TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.

Cancer Cell
Amit ChaudharyB St Croix

Abstract

Current antiangiogenic agents used to treat cancer only partially inhibit neovascularization and cause normal tissue toxicities, fueling the need to identify therapeutic agents that are more selective for pathological angiogenesis. Tumor endothelial marker 8 (TEM8), also known as anthrax toxin receptor 1 (ANTXR1), is a highly conserved cell-surface protein overexpressed on tumor-infiltrating vasculature. Here we show that genetic disruption of Tem8 results in impaired growth of human tumor xenografts of diverse origin including melanoma, breast, colon, and lung cancer. Furthermore, antibodies developed against the TEM8 extracellular domain blocked anthrax intoxication, inhibited tumor-induced angiogenesis, displayed broad antitumor activity, and augmented the activity of clinically approved anticancer agents without added toxicity. Thus, TEM8 targeting may allow selective inhibition of pathological angiogenesis.

References

Aug 19, 2000·Science·B St CroixK W Kinzler
Nov 9, 2001·Nature·K A BradleyJ A Young
Apr 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Heather M ScobieJohn A T Young
Jan 27, 2006·Journal of the American Society of Nephrology : JASN·Vera EreminaSusan E Quaggin
May 25, 2007·Nature Reviews. Cancer·Henk M W Verheul, Herbert M Pinedo
May 29, 2007·Microvascular Research·Arindel S R Maharaj, Patricia A D'Amore
Jun 15, 2007·Cancer Cell·Steven SeamanBrad St Croix
Aug 1, 2007·Nature Biotechnology·Farbod ShojaeiNapoleone Ferrara
Oct 11, 2007·Journal of the National Cancer Institute·Hai-Feng DuanChu-Tse Wu
Nov 3, 2007·The Journal of Biological Chemistry·Shihui LiuStephen H Leppla
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
Jul 8, 2009·Nature Reviews. Clinical Oncology·Helen X Chen, Jessica N Cleck
Jul 18, 2009·Journal of Immunotherapy·Zhihua RuanYuzhang Wu
Jul 21, 2009·Proceedings of the National Academy of Sciences of the United States of America·Shihui LiuStephen H Leppla
Jul 23, 2009·Cancer Research·Mike CullenBrad St Croix
Sep 8, 2010·Targeted Oncology·Priscilla K Brastianos, Tracy T Batchelor
Nov 11, 2010·Future Oncology·Bruce C Baguley, Mark J McKeage
Dec 7, 2010·Biochimica Et Biophysica Acta·Mi Young YangBrad St Croix
Mar 23, 2011·Proceedings of the National Academy of Sciences of the United States of America·Mike CullenBrad St Croix
Apr 21, 2011·Expert Review of Anticancer Therapy·Feng YangDe-Liang Fu

❮ Previous
Next ❯

Citations

Nov 26, 2013·Archives of Pharmacal Research·Golam KibriaHideyoshi Harashima
Feb 2, 2013·PloS One·Hiu-Fung YuenWanJin Hong
Apr 2, 2014·Trends in Microbiology·Shihui LiuStephen H Leppla
Aug 15, 2014·British Journal of Cancer·S TuupanenL A Aaltonen
Jul 2, 2014·Molecular Pharmaceutics·Frank KuoElaine M Jagoda
Dec 2, 2015·Clinical & Experimental Metastasis·Kabir A Khan, Roy Bicknell
Mar 16, 2016·Toxins·Sarah FriebeJérôme Bürgi
Apr 5, 2016·Advanced Drug Delivery Reviews·Erkki Ruoslahti
Jan 13, 2015·Matrix Biology : Journal of the International Society for Matrix Biology·Tatiana Y BesschetnovaBjorn R Olsen
May 24, 2012·Cell Cycle·Amit Chaudhary, Brad St Croix
Mar 18, 2015·PloS One·Sarah FriebeF Gisou van der Goot
Jul 1, 2016·Proceedings of the National Academy of Sciences of the United States of America·Shihui LiuStephen H Leppla
Jun 14, 2017·Journal of Cellular Physiology·Mohammad MashreghiMahmoud R Jaafari
Jun 24, 2015·Molecular and Cellular Biology·Philip J UrenLuiz O F Penalva
Jan 29, 2014·Molecular and Cellular Biology·Hemant K KiniStephen A Liebhaber
Nov 2, 2018·Proceedings of the National Academy of Sciences of the United States of America·Nadishka JayawardenaMihnea Bostina
Mar 1, 2019·Nature Reviews. Clinical Oncology·Elizabeth A KuczynskiAndrew R Reynolds
Dec 18, 2015·International Journal of Molecular Medicine·Sheila C WangWen G Jiang
Jul 27, 2018·Oncotarget·Anette M HøyeJanine T Erler
Oct 18, 2019·PloS One·Kristina PetrovicSteven P Lee
Apr 20, 2014·The Journal of Biological Chemistry·Maria T ArévaloMingtao Zeng
Sep 15, 2019·Cancer Immunology, Immunotherapy : CII·Masoud SotoudehMahmood Naderi
Sep 23, 2018·Cell Communication and Signaling : CCS·Lian-Cheng ZhangXian-Wen Hu
Nov 7, 2019·Cellular and Molecular Life Sciences : CMLS·Roberta LuganoAnna Dimberg
Dec 9, 2014·The Journal of Veterinary Medical Science·Yusuke IzumiMasahiro Okumura
Jun 5, 2018·The Journal of Clinical Investigation·James V McCannAndrew C Dudley
Nov 22, 2018·Frontiers in Oncology·David J EvansJames G Bann
Aug 27, 2019·F1000Research·Oksana A Sergeeva, F Gisou van der Goot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.